New Data Suggest Earlier Olaparib for BRCA+ Ovarian Cancer New Data Suggest Earlier Olaparib for BRCA+ Ovarian Cancer

Results of the SOLO3 trial show that the PARP inhibitor olaparib is a promising strategy for recurrent ovarian cancer.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news